PMC5748101_01
Clinical course. The kinetics of the hematological, cytogenetic, and molecular responses to tyrosine kinase inhibitors and conventional chemotherapy seen during the patient's clinical course are shown. Ara-C: cytosine arabinoside, DNR: daunorubicin, IDR: idarubicin, and ND: not detectable.
CRIHEM2017-3209305.001.jpg
PMC5748101_01_CRIHEM2017-3209305.001.jpg
fig1
Thus, dasatinib was replaced with nilotinib at a reduced dosage of 600 mg/day (Figure 1).